How a Mediterranean Diet and Young-Donor Gut Transplants May Slow Aging

A sweeping new review in Cell Aging & Regeneration argues that some of the most promising anti-aging strategies start in the gut. The review synthesizes evidence across diet, drugs, and cell therapy, but its microbiome section makes a specific, testable claim: the composition of gut bacteria after age 65 tracks with how well the rest of the body ages, and it can be nudged. Two data points anchor that claim. A five-country trial of 1,142 older adults found that a year of eating Mediterranean-style preserved microbial diversity that typically erodes with age, and separate experiments show that giving aged mice gut bacteria from young donors can partially reverse markers of physical decline.

NU-AGE Trial: Mediterranean Diet Preserves Gut Diversity

The clearest human evidence in the review's microbiome section comes from the NU-AGE trial, a one-year Mediterranean-diet intervention conducted across five European countries in adults aged 65 to 79. Across 1,142 participants, researchers tracked how a diet built around vegetables, whole grains, olive oil, and fish shaped the gut microbiome, and the diet group held onto a broader, more diverse mix of bacterial species than participants who kept eating their usual diet. Diversity matters here because a shrinking, less varied microbiome is one of the more consistent biological signatures of aging and frailty. The review credits three overlapping mechanisms for the effect: polyphenols in olive oil and produce get broken down by gut bacteria into compounds with anti-inflammatory activity, omega-3 fats from fish shift bacterial signaling, and fiber from whole grains ferments into short-chain fatty acids that feed the gut lining. The review also flags two specific microbes researchers are watching in this context, the probiotic strain Lacticaseibacillus rhamnosus LM1019 and Akkermansia muciniphila, a species repeatedly linked to metabolic health in aging populations.

Why Microbial Diversity Matters for Frailty

The stakes are practical, not academic. The NU-AGE analysis linked the preserved microbial diversity to reduced frailty and improved markers of physical and cognitive health in the diet group, which matters for a population where frailty, not any single disease, often determines whether someone keeps living independently. The review situates this alongside a separate meta-analysis showing Mediterranean-style eating is tied to an 11 to 30 percent lower risk of age-related cognitive disorders, consistent with the diet's decades-long track record in cardiovascular research. The gut angle adds a mechanism to that track record: rather than just lowering cholesterol or blood pressure, the diet appears to be shaping a microbial community that influences inflammation and metabolism throughout the body. For a 70-year-old, the review's argument is that what's on the plate may matter less for taste than for which bacteria get fed.

From Aged Mice to Human Pilots: Fecal Transplants as a Reset

The review's more speculative thread involves fecal microbiota transplantation, or FMT, the transfer of gut bacteria from one individual to another, as a way to directly reset an aging microbiome. The strongest data here is preclinical: aged mice that received fecal transplants from young donor mice gained grip strength and showed improved metabolic parameters compared to aged mice that didn't, a pattern also reported in related work on young gut microbiota transplants in old mice. That's a mouse finding, and the review is careful to keep it there; grip strength in a mouse cage is not the same as strength in a person. What has moved into humans is more modest: early-stage human pilot studies cited in the review report small gains in insulin sensitivity and reductions in inflammatory markers after FMT, not the more dramatic physical improvements seen in rodents. The review frames FMT as a plausible aging intervention worth continued study, not a validated one.

The Caveats: A Review, Not a New Trial

It's worth being clear about what this paper is and isn't. It's a review, meaning it synthesizes findings from multiple independent trials rather than reporting new original data, and the trials it cites, NU-AGE, the mouse FMT work, CALERIE, SPRINTT, and COLCOT, vary widely in size, design, and rigor. The NU-AGE diet trial is a genuine dietary intervention with over a thousand participants, which is strong by nutrition-research standards; the FMT-in-humans evidence is thinner, drawn from small pilot studies. The excerpt of the review available for this piece also didn't include a visible conflict-of-interest disclosure, which is worth flagging given how commercially active the probiotic and longevity-supplement space has become. None of that undermines the diet findings, which rest on a well-powered trial, but it's a reason to read the FMT section as a promising research direction rather than a treatment recommendation.

What Comes Next: Diet, Drugs, and a Multimodal Playbook

The review's broader argument is that gut-focused strategies work best as one piece of a combined approach, not a standalone fix. It places the microbiome findings alongside other interventions with harder numbers behind them: the CALERIE trial found that sustained caloric restriction slowed epigenetic-clock aging by 2 to 3 percent, the SPRINTT trial found that combining exercise with nutrition counseling cut new mobility-disability events by 22 percent, and the 2024 COLCOT trial found that the anti-inflammatory drug colchicine reduced age-related comorbidity risk by 22 percent and all-cause mortality by 18 percent. Taken together with a mouse study on partial cellular reprogramming that rejuvenated tissue without raising tumor rates, the review's conclusion is that multimodal interventions, diet plus exercise plus, in some cases, medication, consistently outperform any single lever pulled alone. For the microbiome specifically, that means the next round of research is likely to test Mediterranean-style diets, probiotic strains like Akkermansia muciniphila, and FMT protocols not in isolation but stacked with the other approaches that already have trial data behind them.

References

1. XF Yang, RC Zhao, YW Tong, J Cao, H Yin, ZX Wang… (2026). Advances in ANTI-AGING Strategies. Cell Aging & Regeneration,. https://doi.org/10.36922/car025440003
2. NU-AGE trial: Mediterranean diet and gut microbiome in older adults. NIH. https://pmc.ncbi.nlm.nih.gov/articles/PMC7306987
3. CALERIE trial: caloric restriction and epigenetic aging (Nature Aging). Nature. https://www.nature.com/articles/s43587-022-00357-y